Mandate

Vinge has advised Magle Chemoswed Holding AB in connection with its listing on Nasdaq First North Growth Market

Vinge has provided capital markets and transaction advice in connection with Magle Chemoswed Holding AB’s listing on Nasdaq First North Growth Market.

The prospectus was published on 2 June 2020 and trading on Nasdaq First North Growth Market was commenced on 30 June 2020. The offer related to 25 per cent of the total number of existing shares and following full subscription the value of the offer amounted to SEK 50 million.

Magle Chemoswed is an international contract development and manufacturing company and also develops its own product portfolio based on the company’s technology platforms. The company owns its manufacturing and development facilities in Malmö and works in relation to the development and manufacture of pharmaceuticals and medical devices on a contract basis. On 31 March 2020, the company had 70 employees and in 2019, the net turnover amounted to approximately SEK 128 million.

Vinge’s team consisted primarily of Kristian Ford, Christian Lindhé, Martin Svanberg, Sophia Reutercrona, Niklas Törnell, Tilda Hall, Daniel Melander Björner and Johan Cederblad.

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025